examin
relat
cigarett
smoke
occurr
ecaci
vaccin
antibodi
respons
vaccin
famili
practic
southlimburg
netherland
season
data
use
random
doubleblind
placebocontrol
trial
ecaci
vaccin
smoke
statu
measur
week
start
trial
total
subject
age
year
older
subject
smoker
nonsmok
cigarpip
smoker
return
smoke
questionnair
previous
vaccin
use
analys
main
outcom
measur
serolog
fourfold
increas
antibodi
titr
week
month
vaccin
clinic
determin
criteria
dutch
sentinel
station
self
report
symptom
postal
questionnair
week
month
vaccin
increas
vaccin
decreas
month
logarithm
titr
antibodi
vaccin
strain
relat
smoke
either
serolog
clinic
found
although
risk
serolog
slightli
elev
smoker
compar
nonsmok
statist
interact
found
smoke
vaccin
serolog
outcom
measur
indic
ecaci
vaccin
greater
smoker
nonsmok
comparison
model
without
interact
likelihood
ratio
test
p
support
greater
titr
rise
week
vaccin
two
four
strain
antibodi
respons
vaccin
previou
studi
infecti
diseas
also
possibl
dierenc
immunogen
better
protect
clinic
rise
antibodi
titr
week
vaccin
higher
smoker
two
strain
declin
titr
month
similar
smoker
nonsmok
conclud
smoke
clinic
prevent
risk
elderli
studi
found
smoker
suscept
compar
nonsmok
studi
held
among
healthi
young
men
among
gener
popul
mean
age
year
sinc
death
due
occur
among
peopl
age
year
older
focus
eect
smoke
ecaci
vaccin
age
group
morbid
vaccin
elderli
reduc
cohort
studi
random
control
trial
unknown
smoke
group
ecaci
vaccin
antibodi
respons
follow
immun
vaccin
similar
smoker
non
smoker
three
month
show
greater
declin
antibodi
titr
one
year
smoker
impair
persist
serum
antibodi
smoker
immun
vaccin
could
ecaci
vaccin
prevent
object
studi
examin
relat
cigarett
smoke
occurr
ecaci
vaccin
antibodi
respons
vaccin
data
studi
deriv
random
doubleblind
placebocontrol
trial
evalu
ecaci
vaccin
elderli
individu
analyz
eect
smoke
risk
eect
smoke
vaccin
ecaci
clinic
well
serolog
outcom
eect
smoke
antibodi
respons
vaccin
week
rate
increas
month
rate
declin
winter
random
clinic
trial
ecaci
vaccin
elderli
conduct
involv
gener
practition
practic
southlimburg
netherland
person
age
invit
particip
belong
highrisk
group
vaccin
recommend
netherland
age
criterion
recommend
time
total
patient
agre
particip
group
contain
patient
heart
condit
lung
condit
diabet
mellitu
consid
belong
highrisk
group
gener
practition
analysi
restrict
subject
previous
vaccin
detail
recruit
patient
describ
previous
protocol
approv
medic
ethic
committe
univers
limburg
univers
hospit
maastricht
netherland
inform
consent
obtain
form
sign
particip
research
period
cover
month
novemb
april
patient
vaccin
ml
splitvirion
vaccin
n
b
strain
mg
hemagglutinin
intramuscular
placebo
n
physiolog
salin
solut
accord
random
protocol
novemb
ml
venou
blood
taken
particip
pretitr
vaccin
placebo
inject
three
week
later
second
blood
sampl
taken
posttitr
end
follow
month
vaccin
blood
sampl
taken
endtitr
total
patient
indic
vaccin
previous
andor
questionnair
smoke
habit
sent
particip
week
start
investig
total
subject
return
questionnair
inform
gather
smoke
statu
compris
current
smoke
statu
past
smoke
statu
smoke
cigar
pipe
cigarett
amount
cigarett
smoke
everi
day
per
day
per
day
per
day
neversmok
exsmok
group
nonsmok
cigarett
smoker
smoker
leav
rest
group
rest
group
consist
pipe
cigar
smoker
smoke
cigarett
current
previous
antibodi
titr
strain
vaccin
measur
mean
hemagglutinin
inhibit
test
titr
express
reciproc
valu
dilut
hemagglutinin
inhibit
occur
addit
hemagglutin
unit
antigen
titr
less
arbitrarili
set
mean
logarithm
titr
valu
sera
calcul
serum
level
ensur
normal
distribut
rang
titr
valu
use
statist
analys
serum
level
independ
measur
two
analyst
done
sera
sampl
individu
strain
dierenc
logarithm
titr
calcul
smoker
compar
nonsmok
increas
logarithm
titr
valu
calcul
pretitr
posttitr
posttitr
endtitr
titr
greater
fourfold
titr
increas
endtitr
rel
posttitr
taken
criteria
serolog
infect
questionnair
regard
possibl
episod
symptom
sent
particip
week
vaccin
three
criteria
use
diagnos
clinic
accord
famili
physician
dutch
sentinel
station
intern
health
problem
primari
care
least
rigid
criterion
may
caus
falseposit
diagnosi
mani
patient
accord
famili
physician
could
diagnos
patient
consult
physician
followup
period
possibl
miss
patient
visit
physician
criteria
diagnos
clinic
therefor
restrict
criteria
dutch
sentinel
station
analysi
criteria
includ
acut
onset
symptom
fever
least
measur
rectal
least
one
follow
symptom
cough
coryza
sore
throat
frontal
headach
retrostern
pain
myalgia
seri
control
variabl
avail
see
altern
explan
might
exist
relat
interest
variabl
age
sex
risk
group
protect
titr
vaccin
current
vaccin
statu
risk
group
categor
heart
condit
lung
condit
diabet
mellitu
group
condit
titr
greater
strain
greater
b
strain
consid
protect
titr
group
use
analysi
consist
previous
vaccin
subject
test
possibl
relat
smoke
current
vaccin
statu
appli
data
analyz
separ
vaccin
placebo
group
relat
smoke
ecaci
vaccin
smoker
nonsmok
analyz
use
odd
ratio
risk
dierenc
limit
risk
dierenc
calcul
use
formula
cumul
incid
data
describ
rothman
logist
regress
use
correct
age
sex
risk
group
relat
smoke
age
sex
risk
group
protect
titr
vaccin
analys
vaccin
ecaci
two
smoke
group
trend
incid
smoke
categori
nonsmok
day
light
smoker
day
moder
smoker
day
heavi
smoker
evalu
use
regress
analysi
control
age
sex
risk
group
dierenc
vaccin
ecaci
smoker
nonsmok
test
logist
regress
analysi
evalu
interact
vaccin
smoke
control
age
sex
risk
group
done
use
likelihood
ratio
test
describ
kleinbaum
antibodi
respons
express
mean
chang
individu
titr
vaccin
declin
month
analyz
declin
month
subject
serolog
fold
titr
increas
exclud
dierenc
increas
declin
smoker
nonsmok
test
ttest
independ
group
anova
strain
control
age
sex
risk
group
tabl
show
characterist
studi
subject
consist
smoker
nonsmok
pipe
andor
cigar
smoker
rest
smoker
nonsmok
group
similar
regard
current
vaccin
statu
risk
group
protect
titr
vaccin
younger
subject
male
subject
overrepres
among
smoker
serolog
data
incomplet
particip
trial
popul
subject
incomplet
sampl
retain
analys
whenev
possibl
tabl
show
eect
smoke
serolog
clinic
previous
unvaccin
subject
categor
current
vaccin
statu
statist
dierenc
found
placebo
group
higher
rate
serolog
found
smoker
compar
nonsmok
howev
dierenc
statist
vaccin
group
even
revers
true
rate
clinic
dier
smoker
compar
nonsmok
relat
smoke
analyz
use
nonsmok
light
smoker
cigarett
per
day
moder
smoker
per
day
heavi
smoker
per
day
rate
serolog
vaccin
group
nonsmok
light
smoker
moder
smoker
heavi
smoker
trend
p
placebo
group
serolog
increas
nonsmok
light
smoker
moder
smoker
heavi
smoker
trend
p
trend
found
clinic
tabl
show
ecaci
vaccin
smoker
nonsmok
data
hypothesi
smoke
attenu
vaccin
ecaci
rather
revers
true
serolog
outcom
measur
vaccin
smoker
protect
serolog
correct
vaccin
nonsmok
correct
dierenc
ecaci
smoker
nonsmok
statist
likelihood
ratio
test
p
correct
age
sex
risk
group
clinic
outcom
measur
dierenc
ecaci
vaccin
found
smoker
nonsmok
likelihood
ratio
test
p
correct
age
sex
risk
group
tabl
show
mean
logarithm
titr
chang
pretitr
posttitr
posttitr
endtitr
vaccin
group
smoker
compar
nonsmok
great
dierenc
found
pretitr
smoker
compar
nonsmok
adjust
age
sex
risk
group
rise
titr
vaccin
statist
higher
smoker
strain
post
endtitr
declin
margin
higher
smoker
endtitr
still
slightli
higher
smoker
compar
nonsmok
statist
higher
p
adjust
age
sex
risk
group
studi
smoker
greater
incid
serolog
clinic
compar
nonsmok
odd
ratio
smoke
serolog
estim
serolog
data
depict
studi
finklea
et
al
kark
et
al
mackenzi
et
al
or
respect
compar
odd
ratio
found
studi
group
receiv
real
vaccin
placebo
group
result
consist
idea
relat
smoke
somewher
indic
eect
small
studi
trend
among
dierent
smoke
categori
found
serolog
clinic
outcom
variabl
smoke
eect
clinic
studi
howev
finklea
et
al
kark
et
al
relationship
smoke
clinic
odd
ratio
p
p
respect
eect
smoke
would
plausibl
smoke
suscept
viral
infect
well
cohen
et
al
found
smoker
greater
risk
get
common
cold
nonsmok
smoker
like
develop
infect
rhinovirus
respiratori
syncyti
viru
coronaviru
ci
develop
ill
follow
infect
virus
ci
review
cigarett
smoke
summar
studi
respiratori
infect
consist
show
smoker
increas
risk
vaccin
smoker
serolog
ecaci
compar
nonsmok
studi
see
tabl
expect
studi
investig
ecaci
vaccin
smoker
nonsmok
sought
support
antibodi
respons
vaccin
greater
titr
rise
due
vaccin
observ
smoker
compar
nonsmok
two
four
strain
week
vaccin
greater
antibodi
respons
also
found
finklea
et
al
studi
prevaccin
titr
lower
smoker
nonsmok
level
vaccin
possibl
explan
smoker
develop
better
immunolog
protect
vaccin
result
lower
incid
serolog
compar
nonsmok
clinic
relev
appear
low
dierenc
ecaci
vaccin
found
clinic
smoker
nonsmok
studi
also
mackenzi
et
al
knowl
et
al
found
greater
antibodi
respons
smoker
compar
nonsmok
vaccin
vaccin
instead
hepat
b
vaccin
shown
less
immunogen
smoker
versu
nonsmok
sever
studi
exampl
subject
receiv
hepat
b
vaccin
month
standard
schedul
found
vaccin
smoker
lower
antibodi
level
nonsmok
month
summari
tendenc
smoker
higher
antibodi
respons
nonsmok
found
studi
found
studi
vaccin
except
finklea
et
al
hepat
b
vaccin
greater
protect
serolog
smoker
tabl
ecaci
vaccin
smoker
nonsmok
peopl
previous
vaccin
rate
e
correct
covari
f
correct
age
sex
risk
group
protect
titr
vaccin
g
dierenc
ecaci
smoker
nonsmok
likelihood
ratio
p
correct
age
sex
risk
group
tabl
eect
smoke
incid
rate
peopl
previous
vaccin
accord
current
vaccin
statu
rate
compar
nonsmok
found
studi
therefor
hardli
support
immunolog
data
studi
declin
titr
month
vaccin
similar
smoker
nonsmok
consist
knowl
et
al
month
followup
howev
mackenzi
et
al
finklea
et
al
found
depress
persist
hemagglutinationinhibit
antibodi
year
smoker
compar
nonsmok
rais
question
depress
antibodi
titr
smoker
compar
nonsmok
vaccin
manifest
sever
month
howev
question
decid
data
cover
period
month
import
consid
potenti
limit
regard
intern
valid
design
possibl
bia
measur
smoke
statu
could
outcom
clinic
smoke
statu
measur
week
start
investig
howev
hypothes
smoke
known
patient
data
collect
make
unlik
patient
tri
report
smoke
statu
dierent
order
pleas
investig
tri
explain
got
select
bias
unlik
occur
data
use
studi
result
random
clinic
trial
beyer
et
al
palach
gross
et
al
poirier
et
al
point
shortcom
research
vaccin
mani
studi
ecaci
vaccin
prevaccin
titr
previou
vaccin
statu
age
gender
health
statu
taken
account
studi
previous
vaccin
patient
exclud
dierenc
found
pretitr
smoker
nonsmok
correct
made
age
gender
health
statu
also
vaccin
dose
relev
interpret
result
vaccin
dose
subject
activ
season
netherland
domin
strain
therefor
match
geometr
mean
titr
gmt
logtitr
chang
gmt
logchangevalu
logprevalu
logprevalu
ci
indic
interv
b
correct
age
sex
risk
group
protect
titr
vaccin
possibl
intermedi
factor
c
subject
serolog
exclud
titr
endtitr
time
titr
posttitr
caus
small
dierenc
occur
posttitr
use
compar
posttitr
use
least
two
strain
use
vaccin
season
summari
real
threat
valid
result
found
strong
eect
found
studi
slightli
elev
risk
serolog
placebo
group
found
smoker
compar
nonsmok
consist
previou
studi
result
clinic
dierenc
smoker
better
protect
nonsmok
serolog
vaccin
titr
rise
due
vaccin
higher
smoker
nonsmok
strain
howev
littl
support
found
antibodi
respons
vaccin
previou
studi
infecti
diseas
final
smoker
lower
immun
titr
month
vaccin
compar
nonsmok
conclud
smoke
may
enhanc
immunolog
respons
vaccin
smoker
result
higher
protect
serolog
smoker
compar
nonsmok
nevertheless
found
clinic
eect
smoke
risk
vaccin
ecaci
